A self-reported single-site survey of 1,449 pregnant individuals in Rio de Janeiro, Brazil, revealed that 96.6 percent of participants were willing to receive a future Group B Streptococcus vaccine, even though coverage for currently recommended maternal immunizations ranged from 57.6 percent to 75.2 percent.
The study was situated within Brazil’s national immunization program for pregnant people, which the authors describe as robust. However, recent trends in vaccine hesitancy have raised concerns regarding coverage rates and the potential acceptance of forthcoming immunizations, notably vaccines targeting Group B Streptococcus that are currently in late-stage development.
To evaluate these dynamics, researchers assessed coverage for four vaccines recommended during pregnancy and surveyed perceptions regarding a future Group B Streptococcus vaccine. The investigation relied on self-reported data gathered from 1,449 pregnant participants at a single study site located in Rio de Janeiro.
Among the four recommended vaccines evaluated in the survey, vaccine coverage was highest for influenza at 75.2 percent. Uptake was progressively lower for the remaining immunizations, with tetanus, diphtheria, and acellular pertussis (Tdap) reaching 69.9 percent, COVID-19 reaching 68.5 percent, and hepatitis B virus (HBV) recording the lowest coverage at 57.6 percent.
Although an overwhelming majority of 96.6 percent expressed willingness to receive a future Group B Streptococcus vaccine, only 19.9 percent of the surveyed individuals reported awareness of Group B Streptococcus perinatal risks. The authors noted that while coverage for influenza, Tdap, COVID-19, and HBV vaccines varied over time across the study period, willingness to receive the future vaccine remained uniformly high throughout.
The analysis showed that no sociodemographic variable was significantly associated with overall vaccine coverage or vaccine acceptance, with the single exception of marriage being associated with individuals who were not vaccinated for Tdap (p = 0.0207). The researchers concluded that sociodemographic factors did not influence acceptance of the future vaccine within the analyzed study population.
The research examines maternal immunization within Brazil, which maintains a robust national immunization program for pregnant people. Despite the established nature of this public health framework, recent trends in vaccine hesitancy have generated concerns regarding coverage rates for recommended maternal immunizations. In addition to raising questions about existing uptake, these hesitancy trends have introduced uncertainty regarding the acceptance of future vaccines, specifically a Group B Streptococcus vaccine currently in a late stage of development.
To evaluate these maternal immunization patterns, the study analyzed self-reported survey data collected from 1,449 pregnant individuals at a single site in Rio de Janeiro. The investigation assessed coverage across four vaccines recommended during pregnancy: influenza, tetanus, diphtheria, and acellular pertussis (Tdap), COVID-19, and hepatitis B virus (HBV). Across the study, the researchers determined that vaccine coverage varied over time for all four evaluated vaccines.
The recorded figures demonstrated clear variation in coverage among the four evaluated maternal immunizations. Vaccine coverage for influenza was highest at 75.2 percent, followed by Tdap at 69.9 percent and COVID-19 at 68.5 percent. Coverage for the hepatitis B virus vaccine was the lowest among the recommended immunizations, reaching 57.6 percent within the surveyed population.
In contrast to the varying coverage rates observed across the recommended immunizations, willingness to take a future Group B Streptococcus vaccine was uniformly high throughout the study. Overall, 96.6 percent of the pregnant individuals indicated that they were willing to receive the prospective vaccine. However, this high level of willingness contrasted with a low level of disease awareness, as only 19.9 percent of participants were aware of Group B Streptococcus perinatal risks.
The researchers also evaluated whether sociodemographic variables were associated with vaccine coverage or acceptance in the analyzed population. Their analysis revealed that no sociodemographic variable was associated with acceptance of the future vaccine, and sociodemographic factors were broadly unassociated with vaccine coverage. The only statistically significant exception identified was an association between marriage and individuals who were not vaccinated for Tdap (p = 0.0207).
Overall, the findings demonstrate that maternal vaccine coverage in this single-site Rio de Janeiro survey varied across influenza, Tdap, COVID-19, and HBV vaccines over the course of the study, but willingness to take a future Group B Streptococcus vaccine remained consistently high. Furthermore, despite the finding that fewer than one in five individuals were aware of perinatal risks, no sociodemographic aspect was associated with vaccine acceptance in the population analysed.
Subject of Research: Maternal immunization coverage and future vaccine acceptance in Brazil
Article Title: Vaccination survey during pregnancy: five-year trend on vaccine coverage for Tdap, HBV, influenza and COVID-19 and acceptance of a future group B Streptococcus vaccine in Brazil
Article References: Rio-Tinto, A., Bressan, E. O., Merces, A. C., Costa, N. S., Oliveira, L. M. A., Teixeira, L., Fracalanzza, S. E. L., Marinho, P., Amim, J., Jr., & Pinto, T. C. A. (2026). Vaccination survey during pregnancy: five-year trend on vaccine coverage for Tdap, HBV, influenza and COVID-19 and acceptance of a future group B Streptococcus vaccine in Brazil. Frontiers in Global Women's Health, 7, Article 1847100. https://doi.org/10.3389/fgwh.2026.1847100
Image Credits: AI Generated
DOI: 10.3389/fgwh.2026.1847100
Keywords: maternal immunization, pregnancy, vaccine coverage, vaccine hesitancy, Group B Streptococcus, Rio de Janeiro, Brazil, public health, Vaccination, survey, during, five-year
News Source: Kristina Jarvis. (November 10, 2026). Maternal Vaccine Coverage and Future Group B Streptococcus Acceptance Evaluated in Brazil. Scienmag.



